Roman Rodionov: Is Lp(a) Another Homocysteine?
Roman Rodionov, Senior Consultant (Internal and Vascular Medicine, Apheresis), Head of the Angiology Research Lab at Dresden University of Technology, shared a post on LinkedIn:
“Is Lp(a) another homocysteine?
Remember the excitement around homocysteine?
Strong epidemiological associations, plausible biology – but lowering homocysteine ultimately failed to reduce cardiovascular events.
The enthusiasm around Lp(a) over the last year has been remarkable.
We have heard the word causal a lot – while still waiting for the ultimate clinical test: will lowering Lp(a) actually reduce cardiovascular events?
Now Lp(a) HORIZON with pelacarsen has not met its primary endpoint, despite lowering Lp(a).
Does this make Lp(a) another homocysteine?
Probably too early to say.
We need the full results, and other outcome trials are coming.
But more interesting question is: what will be the next big target for residual cardiovascular risk?”
Stay updated with Hemostasis Today.
-
Oct 25, 2026, 19:55Giacomo Buso: LIPLEG Provides the Strongest Evidence to Date on Lipedema Treatment
-
Oct 25, 2026, 19:54Nicholas Lee: ASH Program Connects Trainees and Faculty With Mentors for Career Development
-
Oct 25, 2026, 19:53World Thrombosis Day Raises Blood Clot Awareness at Italian Airports
-
Oct 25, 2026, 19:49Tahsim Anwar: A Six-Year Analysis of Adverse Events in Therapeutic Apheresis
-
Oct 25, 2026, 19:37William Wallace: More than 1 in 3 People with Parkinson’s Were Low in B6
-
Oct 25, 2026, 19:36Andrés Felipe Escobar González: Individualized Treatment Strategies for HMB in BDUC
-
Oct 25, 2026, 19:34Christophe Nougier: Returning to Burundi for the WFH-Supported Twinning Project
-
Oct 25, 2026, 19:29Bogda Koczwara: Pre-Existing and New CVD in Patients With Cancer Are Associated With Higher Mortality
-
Oct 25, 2026, 19:23Özlem Turan: Advancing Care for Women and Girls With Bleeding Disorders at the European Parliament